Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

2021204 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: The Lancet

Volume 397, Issue 10271, pp. 281-292

Field-Weighted Citation Impact: 32.32